ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY25 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY25 earnings guidance on Friday morning. The company provided EPS guidance of $6.12-6.49 for the period, compared to the consensus EPS estimate of $5.56. The company issued revenue guidance of $756-776 million, compared to the consensus revenue estimate of $724.88 million.

ANI Pharmaceuticals Stock Up 13.4 %

ANIP stock opened at $61.89 on Friday. The company has a market cap of $1.30 billion, a P/E ratio of -112.53 and a beta of 0.74. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The company’s 50-day moving average price is $57.06 and its 200 day moving average price is $58.13. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ANIP shares. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

Insiders Place Their Bets

In other news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the transaction, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at approximately $4,131,164.80. This represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,300 shares of company stock worth $584,009. Insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.